FTO and chronic myelogenous leukemia, BCR-ABL1 positive: To this end, we first measured the levels of global m6A amounts and FTO expression, and observed a decrease of m6A abundance (Figure 4A, left; Figure S7a) and an increase of FTO expression (Figure 4A, left) in K562, MV4–11 and Kasumi-1 cells resistant to nilotinib or imatinib, in line with our previous reports.(36) Further, FTO levels were significantly elevated in nilotinib-treated AML patients and in CML patients non-responding to imatinib or nilotinib therapy (Figure S7b).